{"id":56399,"date":"2026-10-26T09:31:36","date_gmt":"2026-10-26T09:31:36","guid":{"rendered":"https:\/\/www.theisn.org\/?p=56399"},"modified":"2026-10-26T09:37:33","modified_gmt":"2026-10-26T09:37:33","slug":"isn-journal-editorial-selections-on-lanreotide-predicting-high-risk-ckd-and-mitochondrial-diseases","status":"publish","type":"post","link":"https:\/\/www.theisn.org\/blog\/2026\/10\/26\/isn-journal-editorial-selections-on-lanreotide-predicting-high-risk-ckd-and-mitochondrial-diseases\/","title":{"rendered":"ISN Journal editorial selections on lanreotide, predicting high-risk CKD, and mitochondrial diseases\u00a0"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text]<\/p>\n

Kidney International<\/span><\/i>\u00ae\u202f<\/span>\u00a0<\/span><\/h3>\n

\"\"<\/span><\/b><\/a><\/p>\n

A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2\/3 autosomal dominant polycystic kidney disease<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

Somatostatin analogues can reduce cyst volume in autosomal dominant polycystic kidney disease (ADPKD), but their effect on kidney function remains uncertain.\u00a0<\/span>\u00a0<\/span><\/p>\n

This three-year randomized, placebo-controlled trial tested whether lanreotide could slow kidney function decline in adults with stage 2\/3 ADPKD.\u00a0<\/span>\u00a0<\/span><\/p>\n

Lanreotide did not slow measured glomerular filtration rate decline, and kidney events and quality of life were similar between groups. Gastrointestinal side effects and hypoglycemia were more common with lanreotide.<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Kidney International Reports\u00ae<\/span><\/i>\u202f<\/span><\/i>\u00a0<\/span><\/h3>\n

\"\"<\/span><\/b><\/a><\/p>\n

Predicting high-risk CKD in Japanese people: model development and validation <\/span><\/b><\/a>\u00a0<\/span><\/p>\n

Validated risk equations to identify people at high risk of chronic kidney disease (CKD) progression can be challenging to apply in primary care in Japan.\u00a0<\/span>\u00a0<\/span><\/p>\n

This study developed and validated a model using routinely available health-check data in Japan to predict progression to high-risk CKD within five years.\u00a0<\/span>\u00a0<\/span><\/p>\n

The model performed well and could support earlier risk assessment and management in primary care, although its applicability outside Japan remains uncertain.<\/span>\u00a0<\/span><\/p>\n

 <\/p>\n

Kidney International Case Reports\u2122<\/span><\/i>\u00a0<\/span><\/h3>\n

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes diagnosed by genetic testing at a freestanding dialysis center: 2 dialysis cases highlighting the diagnostic role of nephrologists<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

Mitochondrial diseases can be difficult to recognize in people receiving dialysis because their symptoms overlap with other conditions and may affect multiple organ systems.\u00a0<\/span>\u00a0<\/span><\/p>\n

This case report describes two patients with longstanding unexplained symptoms who were diagnosed with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes through genetic testing in a dialysis center.\u00a0<\/span>\u00a0<\/span><\/p>\n

The cases highlight how nephrologists\u2019 ongoing contact with dialysis patients can help identify multisystem diseases and prompt further diagnostic evaluation.<\/span>\u00a0<\/span>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_column_text] Kidney International\u00ae\u202f\u00a0 A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2\/3 autosomal dominant polycystic kidney disease\u00a0 Somatostatin analogues can reduce cyst volume in autosomal dominant polycystic kidney disease (ADPKD), but their effect on kidney function remains uncertain.\u00a0\u00a0 This three-year randomized, placebo-controlled trial tested whether lanreotide could slow kidney function decline in adults […]<\/p>\n","protected":false},"author":14,"featured_media":29446,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[98,36],"tags":[510,194,255,591],"class_list":["post-56399","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-journals","category-news","tag-adpkd","tag-ckd","tag-isn-journals","tag-mitochondrial-disease"],"featured_image_src":{"landsacpe":["https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/03\/The-ISN-Journals-3-1024x445.jpg",1024,445,true],"list":["https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/03\/The-ISN-Journals-3-366x246.jpg",366,246,true],"medium":["https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/03\/The-ISN-Journals-3-300x200.jpg",300,200,true],"full":["https:\/\/www.theisn.org\/wp-content\/uploads\/2023\/03\/The-ISN-Journals-3.jpg",1024,681,false]},"_links":{"self":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/posts\/56399"}],"collection":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/comments?post=56399"}],"version-history":[{"count":1,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/posts\/56399\/revisions"}],"predecessor-version":[{"id":56402,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/posts\/56399\/revisions\/56402"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/media\/29446"}],"wp:attachment":[{"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/media?parent=56399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/categories?post=56399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.theisn.org\/wp-json\/wp\/v2\/tags?post=56399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}